Aug 8, 2019 • 4:15pm EDT

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

-- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients -- -- Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) -- ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months e...